Samuel Z. Goldhaber

Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients.

Prospective study of BMI and the risk of pulmonary embolism in women.

Optimal duration of anticoagulation after venous thromboembolism: fixed and evidence-based, or flexible and personalized?

Do take that break.

Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation.

Deep vein thrombosis in orthopedic surgery.

Prescription of fondaparinux in hospitalised patients.

Venous thromboembolism prophylaxis: quality, location (hospital vs. home), and duration.

Ask the doctor. I am due to have a colonoscopy. My cardiologist told me that I will need to stop taking Coumadin, which I take for atrial fibrillation, a few days before the procedure and get some injections. Is this really necessary?

The Surgeon General's call to action exemplifies the role of advocacy in preventing venous thromboembolism.

Venous thromboembolic events in hospitalised medical patients.

Computerized decision support for the cardiovascular clinician: applications for venous thromboembolism prevention and beyond.

Long-term complications of medical patients with hospital-acquired venous thromboembolism.

Medicare's new regulations for deep vein thrombosis as a "never event": wise or worrisome?

Physician alerts to prevent venous thromboembolism.

Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Emotional and psychological coping after venous thromboembolism.

Venous thromboembolism risk and prophylaxis in the acute care hospital setting (ENDORSE survey): findings in surgical patients.

Catheter-directed thrombolysis for giant right atrial thrombus.

Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey.

Ask the doctor. I have been taking ginkgo pills for my memory for several years. I was just diagnosed with atrial fibrillation, and my doctor put me on Coumadin. Is it okay to keep taking ginkgo?

Cognitive function and anticoagulation control in patients with atrial fibrillation.

Fine-tuning risk stratification for acute pulmonary embolism with cardiac biomarkers.

Venous thromboembolism and atherothrombosis: an integrated approach.

Adherence to pharmacological thromboprophylaxis orders in hospitalized patients.

Pulmonary embolism in Black Americans.

Ask the doctor. Last year I had a deep-vein thrombosis with a small pulmonary embolism, apparently precipitated by flying across the country without getting up and walking around. I did just fine with anticoagulation and am now off all medications. Is it safe to fly again? If so, what precautions would you recommend?

Ask the doctor. I am 95 years old and recently began treatment for early macular degeneration in one eye. My retinologist said that PreserVision might help protect the other eye. But she cautioned that it contains a large dose of vitamin E, which could cause a bleeding problem with the Coumadin I take because of a mechanical aortic valve. What would you suggest?

Risk factors for venous thromboembolism.

Diagnosis. Magnetic resonance angiography and venography were sensitive but had poor technical adequacy for diagnosing pulmonary embolism.

Imaging in acute pulmonary embolism with special clinical scenarios.

European Atherosclerosis Society screening recommendations for lipoprotein(a) and high-sensitivity C-reactive protein: double standard or failure of evidence-based medicine?

Eradication of hospital-acquired venous thromboembolism.

Ask the doctor. A year ago, I had an orchiectomy for prostate cancer; my PSA is now 0.74. Not long afterward, I had two cardiac stents implanted. I still have some angina and shortness of breath. I started Ranexa a couple of weeks ago, which helps my angina. Do you have any suggestions for my heart since I no longer make testosterone, which I understand helps protect men's hearts and arteries.

Management of submassive pulmonary embolism.

Embolism after inferior vena cava filter mesh fragmentation.

Prospective study of ABO blood type and the risk of pulmonary embolism in two large cohort studies.

Fibrinolysis for acute pulmonary embolism.

Paradoxical embolism.

Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation.

Controversies in diagnosis of pulmonary embolism.

Ask the doctor. I am a 79-year-old man with atrial fibrillation that is well controlled by Pacerone. I also take warfarin and aspirin to prevent stroke. I plan to have a tooth pulled next month and wonder if is is safe to go off the blood thinners. How are these medications handled when more serious surgery is needed?

Improving Practices in US Hospitals to Prevent Venous Thromboembolism: lessons from ENDORSE.

Chronic thromboembolic pulmonary hypertension.

Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry).

Optimal duration of anticoagulation after venous thromboembolism.

Venous thromboembolism in heart failure: preventable deaths during and after hospitalization.

Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association.

Venous thromboembolic disease.

Physical inactivity and idiopathic pulmonary embolism in women: prospective study.

Peripherally inserted central catheters: bigger is not necessarily better.

Coronary artery revascularization and the risk of death in men with prostate cancer.

CT signs of right ventricular dysfunction: prognostic role in acute pulmonary embolism.

Hospital budget implications of substituting dabigatran for warfarin in an anticoagulation service.

[Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): results obtained in France].

Venous thromboembolism in patients with symptomatic atherosclerosis.

Ask the doctor. My 61-year-old mother plans to take a long plane trip. Her legs usually become swollen when she flies a long distance. Should she wear elastic stockings or take any other precautions so she doesn't develop a blood clot in her legs?

Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels.

Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.

Anticoagulation-associated adverse drug events.

Venous thromboembolism prophylaxis for medical service-mostly cancer-patients at hospital discharge.

The Creating an Optimal Warfarin Nomogram (CROWN) Study.

International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD).

Prospective study of diet and venous thromboembolism in US women and men.

Effect of computerized clinical decision support on the use and yield of CT pulmonary angiography in the emergency department.

Low-molecular-weight heparin and mortality in acutely ill medical patients.

Regional right ventricular strain pattern in patients with acute pulmonary embolism.

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

What's the "go to" anticoagulant for stroke prevention in atrial fibrillation?

Patient education program for venous thromboembolism prevention in hospitalized patients.

Pulmonary embolism and deep vein thrombosis.

Counterpoint: should coagulopathy be repaired prior to central venous line insertion? No.

Venous thromboembolism in patients with diabetes mellitus.

Axial and reformatted four-chamber right ventricle-to-left ventricle diameter ratios on pulmonary CT angiography as predictors of death after acute pulmonary embolism.

Therapy and outcomes in massive pulmonary embolism from the Emergency Medicine Pulmonary Embolism in the Real World Registry.

Venous thromboembolism in patients with chronic obstructive pulmonary disease.

Venous thromboembolism: epidemiology and magnitude of the problem.

Pulmonary embolism: risk assessment and management.

Hospital costs of acute pulmonary embolism.

Rationale supporting an "opt-out" policy for pharmacological venous thromboembolism prophylaxis in hospitalized medical patients.

Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy: a decision analysis.

Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.

Preventing DVT in peripherally inserted central catheters.

Surgical pulmonary embolectomy: the resurrection of an almost discarded operation.

Venous thromboembolism in hospitalized patients with active cancer.

Randomized trial of physician alerts for thromboprophylaxis after discharge.

Rationale and design of the ATTRACT Study: a multicenter randomized trial to evaluate pharmacomechanical catheter-directed thrombolysis for the prevention of postthrombotic syndrome in patients with proximal deep vein thrombosis.

Venous thromboembolism in patients with prior stroke.

Effect of Dabigatran on Referrals to and Switching from Warfarin in Two Academic Anticoagulation Management Services.

Improving clinician performance of inpatient venous thromboembolism risk assessment and prophylaxis.

Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry.

Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial.

Venous thromboembolic disease.

A pharmacogenetic versus a clinical algorithm for warfarin dosing.

Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.

Risk assessment to predict arterial and venous events in patients undergoing percutaneous coronary intervention.

Race and venous thromboembolism: nature or nurture?

Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.

The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study.

Fibrinolysis for patients with intermediate-risk pulmonary embolism.

D-Dimer elevation and adverse outcomes.

Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment.

Medication use evaluation: pharmacist rubric for performance improvement.

Cardiology Patient Page: inflammation and myocardial infarction.

Predictive Value of Computed Tomography in Acute Pulmonary Embolism: Systematic Review and Meta-analysis.

Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation.

Regulatory, legislative, and policy updates with anticoagulant use.

Performance of Wells Score for Deep Vein Thrombosis in the Inpatient Setting.